ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CARA Cara Therapeutics Inc

0.3746
0.0062 (1.68%)
Pre Market
Last Updated: 12:00:08
Delayed by 15 minutes
Share Name Share Symbol Market Type
Cara Therapeutics Inc NASDAQ:CARA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.0062 1.68% 0.3746 0.3646 0.37 100 12:00:08

Cara Therapeutics to Announce First Quarter 2017 Financial Results on May 4, 2017

27/04/2017 1:00pm

GlobeNewswire Inc.


Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Cara Therapeutics Charts.

Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Thursday, May 4, 2017, at 4:30 p.m. ET to report first quarter 2017 financial results and provide a corporate update.

To participate in the conference call, please dial 855-445-2816 (domestic) or 484-756-4300 (international) and refer to conference ID 10052639. A live webcast of the call can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.

An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.

About Cara Therapeutics 

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara Therapeutics is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

INVESTOR CONTACT:
Michael Schaffzin
Stern Investor Relations
212-362-1200
michael@sternir.com

MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838 
astarr@6degreespr.com

1 Year Cara Therapeutics Chart

1 Year Cara Therapeutics Chart

1 Month Cara Therapeutics Chart

1 Month Cara Therapeutics Chart

Your Recent History

Delayed Upgrade Clock